Dr. Natalie S. Grover
Claim this profileLineberger Comprehensive Cancer Center at University of North Carolina
Area of expertise
Lymphoma
Natalie S. Grover has run 6 trials for Lymphoma. Some of their research focus areas include:
Hodgkin's Lymphoma
Natalie S. Grover has run 4 trials for Hodgkin's Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Lineberger Comprehensive Cancer Center At University Of North Carolina
UNC Lineberger Comprehensive Cancer Center
Clinical Trials Natalie S. Grover is currently running
Epcoritamab
for Lymphoma
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings the two cells together and activates the T-cells to kill the cancerous B-cells. Epcoritamab may increase a patient's chances of achieving complete remission after CD19-directed CAR-T therapy, compared to standard observation.
Recruiting
1 award
Phase 2
Cell Therapy
for Hodgkin's Lymphoma
Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only to further reduce mortality but also to alleviate morbidity. The majority of HL express the CD30 antigens. CD30 expression is routinely used for the diagnosis of HL. Preclinical observations support CD30 as a viable target of CAR-T therapy. This phase Ib/II study was conducted based on these observations. The purpose of this study is to determine the tolerability of ATLCAR.CD30.CCR4 cells in subjects with Hodgkin's Lymphoma and identify a recommended dose for further. This is a single-center, open-label phase Ib/II trial that uses a 3+3 design to identify a recommended phase 2 dose (RP2D) of ATLCAR.CD30.CCR4 cells in Hodgkin's Lymphoma. The phase II portion is designed to determine the PFS of ATLCAR.CD30.CCR4 in Hodgkin's Lymphoma. Subjects will be enrolled on 1 of 3 dose levels as determined by a 3+3 design. Up to 25 evaluable subjects may then be enrolled in the phase II portion of the study. Subjects may have cells procured to manufacture the ATLCAR.CD30.CCR4 cells if they meet eligibility for procurement. During the time period necessary to manufacture the ATLCAR.CD30.CCR4 cells, Subjects will be allowed to receive standard-of-care bridging therapy at the discretion of their local oncologist. Prior to cell infusion, subjects will undergo additional eligibility evaluations, and then if eligible, will undergo lymphodepletion followed by cell infusion 2-14 days later. Subjects will then be followed for 15 years as is required for studies involving gene transfer experiments.
Recruiting
1 award
Phase 1 & 2
6 criteria
More about Natalie S. Grover
Clinical Trial Related
2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Natalie S. Grover has experience with
- Nivolumab
- Bendamustine
- Cyclophosphamide
- Fludarabine
- ATLCAR.CD30.CCR4
- Brentuximab Vedotin
Breakdown of trials Natalie S. Grover has run
Hodgkin's Lymphoma
Immune Dysfunction
Immunoproliferative Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Natalie S. Grover specialize in?
Natalie S. Grover focuses on Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CD30 positive patients, or patients who are CD19 positive.
Is Natalie S. Grover currently recruiting for clinical trials?
Yes, Natalie S. Grover is currently recruiting for 5 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Natalie S. Grover has studied deeply?
Yes, Natalie S. Grover has studied treatments such as Nivolumab, Bendamustine, Cyclophosphamide.
What is the best way to schedule an appointment with Natalie S. Grover?
Apply for one of the trials that Natalie S. Grover is conducting.
What is the office address of Natalie S. Grover?
The office of Natalie S. Grover is located at: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the Lineberger Comprehensive Cancer Center at University of North Carolina.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.